Metformin linked with better survival in RCC patients with diabetesApril 10, 2017Renal Cell CarcinomaGenitourinary Cancer
No benefit from adjuvant sunitinib or sorafenib for clear cell renal cancerMarch 9, 2017Renal Cell CarcinomaGenitourinary Cancer
Genomic differences seen in mRCC during first- and second-line therapyFebruary 28, 2017Genitourinary CancerRenal Cell CarcinomaImmuno-oncology
Clinical benefit persists for some with mRCC after stopping immune checkpoint blockadeFebruary 15, 2017Genitourinary CancerRenal Cell Carcinoma
Staying the course after first progression yields better mRCC survivalFebruary 10, 2017Renal Cell CarcinomaGenitourinary Cancer
Intermittent breaks from sunitinib feasible in metastatic RCCJanuary 30, 2017GastroenterologyRenal Cell CarcinomaGastrointestinal Cancer
ASCO offers practice guidance on small renal massesJanuary 19, 2017Genitourinary CancerClinical GuidelinesRenal Cell Carcinoma
AKT inhibition not superior to everolimus for RCCJanuary 10, 2017Genitourinary CancerRenal Cell Carcinoma
Genetics dictate interferon-alfa diarrhea riskDecember 6, 2016GastroenterologyPreventive CareRenal Cell CarcinomaGastrointestinal Cancer
Cabozantinib bests sunitinib against metastatic RCCNovember 14, 2016Genitourinary CancerRenal Cell Carcinoma
FDA approves nivolumab for advanced squamous cell carcinoma of the head and neckNovember 11, 2016Head & Neck/Thyroid CancersRenal Cell Carcinoma
Cabozantinib used as first-line therapy prolongs PFS for metastatic RCCOctober 15, 2016Genitourinary CancerRenal Cell Carcinoma
Adjuvant sunitinib offers DFS edge in high-risk RCCOctober 14, 2016Genitourinary CancerRenal Cell Carcinoma
FDA modifies dosage regimen for nivolumabSeptember 19, 2016Lung CancerGenitourinary CancerLymphoma & Plasma Cell DisordersMelanomaRenal Cell Carcinoma
